Evercore ISI Reiterates In-Line Rating for COMPASS Pathways (NASDAQ:CMPS)

Evercore ISI reaffirmed their in-line rating on shares of COMPASS Pathways (NASDAQ:CMPS - Free Report) in a research report released on Monday, MarketBeat Ratings reports. Evercore ISI currently has a $6.00 price objective on the stock, down from their prior price objective of $11.00.

CMPS has been the topic of several other research reports. Canaccord Genuity Group decreased their target price on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $12.00 price objective on shares of COMPASS Pathways in a report on Tuesday, May 27th. Stifel Nicolaus started coverage on COMPASS Pathways in a report on Thursday, February 27th. They set a "buy" rating and a $11.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $45.00 target price on shares of COMPASS Pathways in a research report on Monday, May 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $17.00.

COMPASS Pathways Stock Down 3.6%

Shares of CMPS stock traded down $0.10 during trading on Monday, reaching $2.66. The company's stock had a trading volume of 4,335,050 shares, compared to its average volume of 1,163,635. The company has a market cap of $248.87 million, a price-to-earnings ratio of -1.34 and a beta of 2.25. COMPASS Pathways has a one year low of $2.25 and a one year high of $8.54. The business has a fifty day moving average price of $4.06 and a 200-day moving average price of $3.86. The company has a quick ratio of 10.18, a current ratio of 10.18 and a debt-to-equity ratio of 0.11.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.03. Analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Trading of COMPASS Pathways

Several hedge funds have recently added to or reduced their stakes in CMPS. Cerity Partners LLC purchased a new stake in COMPASS Pathways during the first quarter valued at about $29,000. GAMMA Investing LLC increased its position in shares of COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock worth $30,000 after purchasing an additional 5,003 shares during the last quarter. Ethos Financial Group LLC bought a new position in COMPASS Pathways in the first quarter valued at $35,000. Flagship Harbor Advisors LLC grew its position in COMPASS Pathways by 27.7% during the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after acquiring an additional 3,134 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in shares of COMPASS Pathways in the 1st quarter valued at about $41,000. Institutional investors own 46.19% of the company's stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.